JLJose G. Lazo

Jose G. Lazo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jose G. Lazo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Care of Adult Heart Transplant Recipients by the Primary Care Provider: A Practical Roadmap

    by Yu Wu, Lina Gao, Jose Lazo, Brandon Martinez, Simran Grewal, Irina Yurkova, Julia Galeota, Catherine Nash, Meghan Cutler, Nimaljeet Tarango, et al.

    Heart transplantation has significantly improved survival and enhanced the quality of life of patients with end-stage heart failure. Successful long-term outcomes are predicated on a collaborative effort among patients, transplant teams, and primary care providers (PCPs). Notably, PCPs are increasingly pivotal in post-transplant care, engaging in annual assessments, early recognition of complications, and referral, thus minimizing morbidity and mortality. This article highlights key considerations for PCPs, including indications for heart transplant, immunosuppressive therapy and infection prophylaxis, management of post-transplant complications, psychosocial and lifestyle adjustment, and family planning. This roadmap aims to empower PCPs to deliver optimal care and improve long-term outcomes for heart transplant recipients.


  • To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years

    by John G. Rizk, Aashish Gupta, Jose G. Lazo, Partha Sardar, Brandon Michael Henry, Carl J. Lavie, Mark B. Effron

    A hypercoagulable state associated with coronavirus disease 2019 (COVID-19) has been well documented and is believed to be strongly supported by a proinflammatory state. The hypercoagulable state in turn results in increased incidence of arterial and venous thromboembolism (VTE) seen in hospitalized COVID-19 when compared with hospitalized non-COVID-19 patient cohorts. Moreover, patients with arterial or VTE and COVID-19 have higher mortality compared with COVID-19 patients without arterial or VTE. Prevention of arterial or VTE thus remains an essential question in the management of COVID-19 patients, especially because of high rates of reported microvascular and macrovascular thrombosis. This has prompted multiple randomized control trials (RCTs) evaluating different anticoagulation strategies in COVID-19 patients at various stages of the disease. Herein, we review findings from RCTs in the past 2 years of antithrombotic therapy in critically ill hospitalized patients, noncritically ill hospitalized patients, patients postdischarge from the hospital, and outpatients. RCTs in critically ill patients demonstrated therapeutic dose anticoagulation does not improve outcomes and has more bleeding than prophylaxis dose anticoagulant in these patients. Trials in noncritically ill hospitalized patients showed a therapeutic dose anticoagulation with a heparin formulation might improve clinical outcomes. Anticoagulation with a direct oral anticoagulant posthospital discharge may improve outcomes, although there is a large RCT in progress. Nonhospitalized COVID-19 patients have an insufficient burden of events to be candidates for antithrombotic therapy. Anticoagulation in pregnant and lactating patients with COVID-19, as well as antiplatelet therapy for COVID-19, is also reviewed. * These authors contributed equally (co-first authors). Publication Date: 25 April 2022 (online) © 2022. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA